B/BE/21/BVW6 - Fiche d'information destinée au public (préparée par le notifiant)

File: 
PDF icon bbe21bvw6_pub_fr.pdf
Trial reference: 
A phase 2, single-blinded, randomized, controlled multi-country study to evaluate the safety,reactogenicity, efficacy and immune response following sequential treatment with an antisense oligonucleotide (ASO) against chronic Hepatitis B (CHB) followed by
Doc type: 
Information for the public